Here you will find the Funding Position of CCG Commissioned High-Cost Drugs within the Lancashire and South Cumbria Health Economy
A number of High-Cost Drugs, devices, procedures and products have been excluded from the scope of the national tariff of Payment by Results. These are listed on tab 13b of the following document:
2024/25 Annex A: The national tariff workbook
High-cost drugs are commissioned by:
The funding position of medicines directly commissioned by NHS England can be accessed via the NHS England website
Refer to the Manual for Prescribed Specialised Services for further information about prescribed specialised services, some of which are directly commissioned by NHS England and some by CCGs.
Date Posted: 01 - Oct - 2019
Approval Mechanism: Prior approval blueteq form available
Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Date Posted: 05 - Mar - 2020
Approval Mechanism:
Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)
Date Posted: 05 - Mar - 2020
Approval Mechanism: Prior Approval Blueteq Form Available
Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)
Date Posted: 01 - Oct - 2019
Approval Mechanism: Prior approval blueteq form available
Unlicensed use in non-acute treatment of recurrent gastrointestinal bleeding disorders (including angiodysplasia, small bowel dysplasia, gastric antral vascular ectasia, haemorrhagic telangiectasia)
Date Posted: 05 - Mar - 2020
Approval Mechanism:
Unlicensed use for orthostatic intolerance disorders e.g. postural orthostatic tachycardia syndrome (PoTS)
Date Posted: 05 - Mar - 2020
Approval Mechanism: Prior Approval Blueteq Form Available
Unlicensed use in Secretory Gastrointestinal Disorders (e.g. enterocutaneous fistula, high output stoma and refractory diarrhoea)
Date Posted: 01 - Sep - 2018
Approval Mechanism: Blueteq
Autoimmune haemolytic anaemia
Date Posted: 01 - Sep - 2018
Approval Mechanism: Blueteq
Idiopathic thrombocytopenia purpura
Date Posted: 01 - Jul - 2018
Approval Mechanism:
Membranous glomerulonephritis
Date Posted: 01 - Jul - 2018
Approval Mechanism:
Relapsing steroid sensitive nephrotic syndrome in adults
